Castillo-Huerta E, Garibay-Valencia M, Mirabent-González F

Language: Spanish
References: 23
Page: 370-376
PDF size: 583.30 Kb.

ABSTRACT

Background: Fibrocystic breast disease is one of the most frequent conditions of the breast among women from 30 to 49 years, with a frequency of about 60%, hence the interest in studying and treating it with the most advanced and effective resources.
Objective: To compare the efficacy and adverse events of alpha dihydroergocryptine with cabergoline in patients with fibrocystic breast disease.
Material and Methods: A prospective, longitudinal, open, comparative study between alpha-dihydroergocryptine and cabergoline, made in the service of Gynecology and Obstetrics at the Dr. Miguel Silva General Hospital in Morelia, Michoacán. 171 patients diagnosed with fibrocystic breast disease were randomly assigned to the alpha-dihydroergocryptine or the cabergoline group. Assessments were made at baseline and every month subsequently. The following symptoms were evaluated: breast tenderness, breast pain, lumps and nipple discharge. The concentrations of prolactin were determined and an ultrasound was performed at baseline and at 3 and 6 months, patients were questioned about adverse events.
Results: 171 patients were included (81 treated with alpha-dihydroergocryptine and 90 with cabergoline); 156 completed the study. The age limits were 18 and 51 years. The evolution time prior to study entry was 17.71 ± 18.3 months for the alpha-dihydroergocryptine group and 18.57 ± 20.35 for the cabergoline group. 15 patients discontinued treatment due to adverse events (8 of the alpha-dihydroergocryptine group and 7 of the cabergoline group). The most common adverse event was headache.
Conclusions: In this study alpha-dihydroergocryptine was better tolerated and had better clinical response compared with cabergoline; breast pain and breast tenderness disappeared within the first month of treatment. Adverse events were similar for both treatments.

REFERENCES

1. Sterns EE. The natural history of macroscopic cysts in the breast. Surg Gynecol Obstet 1992;174:36-40.

2. Guray M, Sahin A. Benign Breast Diseases: Classification, Diagnosis, and Management. The Oncologist 2006;11:435-449.

3. Schorge JO, Schaffer JI, Pietz J, Halvorson LM, Hoffman BL, Bradshaw KD, et al. Breast Disease. In: Schorge JO, Schaffer JI, Pietz J, Halvorson LM, Hoffman BL, Bradshaw KD, et al, editors. Williams Gynecology. New York: McGraw-Hill, 2011.

4. Ferrari P, Bargellini A, Messori D, Favero A. Accurate diagnosis by mammary echotomography. Minerva Med 1990;81(3 Suppl):5-12.

5. Fitzal P, Wolf G. Comparison of the diagnostic value of the individual examination steps (triple diagnosis) in breast cysts. Ultraschall Med 1990;11:202-205.

6. Strasser K, Buchberger W, Hamberger L, Ebner K, Totsch M, Muller E. Sonography in breast diagnosis. Radiologe 1990;30:130-134.

7. Ishii M. The study of ultrasonographic diagnosis on breast diseases. Nippon Igaku Hoshasen Gakkai Zasshi 1992;52: 1033-1035.

8. Kubista E. Diagnosis and therapy of fibrocystic breast disease. Zentralbl Gynakol 1990; 112:1091-1096.

9. Schindler, AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch Gynecol Obstet 2011;283:369-371.

10. Mainero Ratchelous FE, Aguilar Gallegos UI. Guías de práctica clínica 2008. Tratamiento de la mastalgia. Ginecol Obstet Mex 2009;77:S371-S390.

11. Mousavi SR, Rezaei M. Tamoxifen effects on treatment fibrocystic breast disease in women. Saudi Med J 2006;27:565-566.

12. Olawaiye A, Withiam-Leitch M, Danakas G, Kahn K. Mastalgia: a review of management. J Reprod Med 2005;12:933-939.

13. Garci RF, Pena Cortes TH. Ultrasonographic images of fibrocystic mastopathy treated with bromocriptine. Ginecol Obstet Mex 1986;54:274-277.

14. Tolino A, Cardone A, Mastrantonio P, Chiacchio G. Treatment of benign breast pathology with bromocriptine. Riv Ital Ginecol 1977;58:371-378.

15. Mussa A, Sandrucci S, Dogliotti L. Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline. Minerva Med 1979;70:3493-3498.

16. Mussa A, Dogliotti L. Treatment of benign breast disease with bromocriptine. J Endocrinol Invest 1979;2:87-91.

17. Marzetti L, Framarino ML, Dei Malatesta ML, Aragona C, De AR. Bromocriptine in fibro-cystic mastopathy. Riv Ital Ginecol 1980;59:357-364.

18. Santoro C, Cappa M, Moretti C, Fabbri A, La V, V, Romano ML, et al. Treatment of benign fibrocystic disease of the breast with 2-bromo-alpha-ergocryptine (CB 154). Int J Clin Pharmacol Ther Toxicol 1982;20:479-481.

19. López R, Castellanos R. Tratamiento de la mastopatía fibroquística con bromocriptina. Ginecol Obstet Mex 1985;53:233-236.

20. Ablanedo J, Canales E. Resultados del tratamiento crónico con bromocriptina en pacientes con mastopatía fibroquística. Arch invest Med 1988;3:225-229.

21. López RC, Romero Espinosa RE, Juárez VJ. Treatment of fibrocystic breast disease with lisuride. Ginecol Obstet Mex 1991;59:358-361.

22. Castillo E, Garibay M, Mirabent F. Efecto de la alfa dihidroergocriptina en pacientes con enfermedad fibroquística mamaria. Ginecol Obstet Mex 2006;74:580-584.

23. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255-279.